---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073401"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:59:26.464401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1

## Summary
- Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.
- FY25 revenue $112.8M (-6%); GAAP loss ($0.70)/share; adjusted EPS $0.11; adjusted EBITDA $5.3M.
- Commercial Channel rev +22% Q4, +15% FY; OEM -12% Q4, -17% FY.
- FY26 guidance: rev $114-122.5M (1-9% growth); adj. EBITDA margin 5-10%; $15M buyback continuing.
- EVP, General Counsel David Colleran to depart May 1, 2026 under transition agreement.

## SEC filing metadata
- accession: 0001193125-26-073401
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000119312526073401/0001193125-26-073401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000119312526073401/d106406d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073401
- JSON: https://secwatch.observer/filing/0001193125-26-073401.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.